Cambridge Healthtech Institute’s 4th Annual
Early Cancer Surveillance
Multi- and Single-Cancer Early Detection: Validation of Improved Early Screening
August 18-19, 2025
There is widespread agreement that the ability to screen for and detect cancer at earlier stages could have a significant impact on reducing morbidity and mortality. It also makes sense that the ability to screen for many different types of cancer in one assay would provide huge advantages compared to single cancer screens. With only five cancers currently having recommended screens and compliance with these recommendations being only fair to poor, there is considerable room for improvement. At the same time, liquid biopsies for each detection face real health economic challenges, particularly for screening of the general population as opposed to higher-risk patients. Early-stage cancers typically do not provide robust signals, those are the cases where early detection can make the greatest impact. Progress for improved assays, evaluation of different biomarker classes or combinations, and results from clinical validation studies will be provided. Hear from many of the leading developers of single- and multi-cancer early detection tests and learn about the latest trends and competitive issues.
Coverage will include, but is not limited to:
- Updates of the development and validation of specific assays
- General population testing compared to focusing on high-risk patients
- Health economics and the impact on pricing, accessibility, and equity
- Different biomarker classes (DNA, RNA, proteins, metabolites and multiomic)
- Clinical trial design considerations for validation of performance
- Obstacles to adoption of changes in medical testing practice
- Diagnostic follow-up strategies after positive MCED results
- The impact of increased early detection on tolerance of toxic cancer therapies
The deadline for priority consideration is January 27, 2025.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: